There was a 3-fold increase in CVAE in patients treated with olanzapine compared to patients treated with placebo (1.3% vs.
Olansapiiniga ravitud patsientidel esines kolm korda rohkem AVKT- id kui platseebo patsientidel (vastavalt 1, 3% ja 0, 4%).